Clinical trial · no report yet · Phase 3
CERVINO
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
- NCT06158841 ↗
- Active not recruiting
- AbbVie
- 61 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 51 | |
| YouTube | 8 | |
| Podcasts | 1 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Multicenter, Randomized, Open Label Study of Etentamig Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Etentamig; Carfilzomib; Pomalidomide; Elotuzumab; Selinexor; Bortezomib; Dexamethasone
- Arms
- Etentamig · Experimental
- Standard Available Therapy (SAT) · Experimental
- Enrollment
- 421
- Primary outcomes
- Progression Free Survival (PFS)
- Objective Response Rate (ORR)
- Sponsor
- AbbVie
- Start
- May 19, 2024
- Primary completion
- Dec 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06158841 · updated Aug 27, 2026